We are live on ! Find out more
PBA

Paradigm Biocapital Advisors Portfolio holdings

AUM $4.89B
1-Year Est. Return 251.12%
This Fund
S&P 500
This Quarter Est. Return
-1.92%
1 Year Est. Return
+251.12%
3 Year Est. Return
+670.11%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2.61B
AUM Growth
-$228M
Cap. Flow
-$39.5M
Cap. Flow %
-1.51%
Top 10 Hldgs %
64.57%
Holding
44
New
10
Increased
10
Reduced
11
Closed
9

Top Buys

Rank Stock Value
1
MRUS
Merus
MRUS
+$97.8M
2
RVMD icon
Revolution Medicines
RVMD
+$87.6M
3
JANX icon
Janux Therapeutics
JANX
+$73.5M
4
BBIO icon
BridgeBio Pharma
BBIO
+$29.8M
5
KURA icon
Kura Oncology
KURA
+$28.9M

Top Sells

Rank Stock Value
1
IMCR icon
Immunocore
IMCR
+$116M
2
ALPN
Alpine Immune Sciences Inc
ALPN
+$84.1M
3
BCYC
Bicycle Therapeutics
BCYC
+$80.8M
4
PCVX icon
Vaxcyte
PCVX
+$41.7M
5
AUTL
Autolus Therapeutics
AUTL
+$41M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NUVL
1
DELISTED
Nuvalent
NUVL
$347M 13.27%
4,571,678
+393,848
+9% +$28M
ARGX icon
2
argenx
ARGX
$57.4B
$231M 8.86%
538,139
-13,981
-3% -$5.35M
ACLX
3
DELISTED
Arcellx
ACLX
$212M 8.13%
3,848,095
+30,000
+0.8% +$1.63M
RVMD icon
4
Revolution Medicines
RVMD
$40.2B
$204M 7.81%
5,259,089
+2,344,114
+80% +$87.6M
SRPT icon
5
Sarepta Therapeutics
SRPT
$1.66B
$150M 5.73%
947,574
-130,772
-12% -$16.8M
IRON icon
6
Disc Medicine
IRON
$2.83B
$122M 4.67%
2,704,718
+314,816
+13% +$10.7M
MRUS
7
DELISTED
Merus
MRUS
$120M 4.57%
+2,019,814
New +$97.8M
CRNX icon
8
Crinetics Pharmaceuticals
CRNX
$8.86B
$113M 4.31%
2,513,302
-611,447
-20% -$28.2M
CERE
9
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
$95.3M 3.65%
2,330,508
– –
KURA icon
10
Kura Oncology
KURA
$922M
$93.5M 3.58%
4,539,381
+1,403,994
+45% +$28.9M
ASND icon
11
Ascendis Pharma A/S
ASND
$16.7B
$90.6M 3.47%
664,307
+156,355
+31% +$21.3M
OLMA icon
12
Olema Pharmaceuticals
OLMA
$1.02B
$85.5M 3.27%
7,903,600
– –
XENE icon
13
Xenon Pharmaceuticals
XENE
$6.32B
$79.7M 3.05%
2,043,280
-441,594
-18% -$17.7M
TARS icon
14
Tarsus Pharmaceuticals
TARS
$2.56B
$66.2M 2.53%
2,435,416
-427,990
-15% -$14.4M
JANX icon
15
Janux Therapeutics
JANX
$935M
$65.5M 2.51%
+1,564,452
New +$73.5M
ARVN icon
16
Arvinas
ARVN
$518M
$64.9M 2.48%
2,438,149
-176,786
-7% -$5.63M
LEGN icon
17
Legend Biotech
LEGN
$4.3B
$53.3M 2.04%
1,203,308
-778,698
-39% -$35.9M
PCVX icon
18
Vaxcyte
PCVX
$7.89B
$47.4M 1.81%
627,202
-612,793
-49% -$41.7M
YMAB
19
DELISTED
Y-mAbs Therapeutics
YMAB
$46.8M 1.79%
3,870,594
+1,636,984
+73% +$22.1M
EWTX icon
20
Edgewise Therapeutics
EWTX
$4.39B
$41.9M 1.6%
2,325,449
-120,924
-5% -$2.11M
IMTX icon
21
Immatics
IMTX
$1.24B
$39.8M 1.52%
3,421,965
+603,057
+21% +$6.8M
VRDN icon
22
Viridian Therapeutics
VRDN
$2.13B
$37.7M 1.44%
2,896,349
-2,135,071
-42% -$29.6M
IMVT icon
23
Immunovant
IMVT
$8.09B
$36M 1.38%
1,362,827
+563,773
+71% +$16M
COGT icon
24
Cogent Biosciences
COGT
$6.79B
$30.6M 1.17%
+3,624,342
New +$27.5M
BBIO icon
25
BridgeBio Pharma
BBIO
$16.5B
$27.6M 1.06%
+1,089,492
New +$29.8M
1
2

Similar funds

KCM
Kensico Capital Management Greenwich, Connecticut $4.9B AUM 41.26% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
FC
Freemont Capital Singapore $4.91B AUM 5.45% 1-Year Est. Return
WTC
WhitTier Trust Company Reno, Nevada $4.87B AUM 25.35% 1-Year Est. Return
MCM
Moore Capital Management New York $4.92B AUM 35.41% 1-Year Est. Return
MSRPS
Maryland State Retirement & Pension System Baltimore, Maryland $4.92B AUM 28.48% 1-Year Est. Return
MCCA
Mill Creek Capital Advisors Conshohocken, Pennsylvania $4.87B AUM 17.69% 1-Year Est. Return
SIA
Sit Investment Associates Minneapolis, Minnesota $4.93B AUM 12.22% 1-Year Est. Return

Paradigm Biocapital Advisors's Q2 2024 Portfolio in Review

As of Q2 2024, Paradigm Biocapital Advisors held 44 positions worth $2.61B, down 8% from $2.84B the previous quarter. Its ten largest holdings account for 65% of the portfolio.

Paradigm Biocapital Advisors's Q2 2024 filing shows 10 new, 10 increased, 11 reduced and 9 closed positions. Its largest new stake was Merus: 2,019,814 shares worth $120M. The largest sale was Immunocore, an estimated $116M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Paradigm Biocapital Advisors's largest Q2 2024 buy was Merus: 2,019,814 shares worth $120M.
  • Paradigm Biocapital Advisors added most to Revolution Medicines in Q2 2024, an estimated $87.6M increase.
  • Paradigm Biocapital Advisors's biggest Q2 2024 reduction was Vaxcyte, cutting an estimated $41.7M.
  • Paradigm Biocapital Advisors fully exited Immunocore in Q2 2024, selling an estimated $116M.
  • Paradigm Biocapital Advisors's ten largest holdings make up 65% of its $2.61B portfolio in Q2 2024.
  • Paradigm Biocapital Advisors opened 10 new positions and closed 9 in Q2 2024.
  • Paradigm Biocapital Advisors's portfolio value fell 8% quarter-over-quarter to $2.61B.

Based on Paradigm Biocapital Advisors's 13F filing for Q2 2024, filed 14 Aug 2024.